Article Text

Download PDFPDF

Letter
Iloprost-induced rash
Free
  1. R S Finn1,
  2. L Beckert2,
  3. R Troughton3
  1. 1
    Canterbury District Health Board, Respiratory Department, Christchurch Hospital, Christchurch, New Zealand
  2. 2
    Canterbury District Health Board, Respiratory Laboratory, Christchurch Hospital, Christchurch, New Zealand
  3. 3
    Canterbury District Health Board, Cardiology Department, Christchurch Hospital, Christchurch 8011, New Zealand
  1. Correspondence to Dr L Beckert, Canterbury District Health Board, Respiratory Laboratory, 4th Floor, Riverside Block, Christchurch Hospital, Christchurch 8011, New Zealand; Lutz.Beckert{at}cdhb.govt.nz

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We report a 59-year-old woman with a background history of CREST syndrome (calcinosis, Raynaud phenomenon, (o)esophageal dysmotility, sclerodactyly and telangiectasia) and secondary pulmonary hypertension who presented with a bilateral lower limb vasculitic rash.

A couple of weeks earlier she had been initiated on nebulised iloprost (Ventavis; Bayer New Zealand, Auckland, New Zealand) for progression of her pulmonary hypertension while on treatment with Sildenafil. She started on 20 μg three times a day, increasing every 3 days to a total of 20 μg every 4 h. Within a few days of reaching the maximum dose she developed a painful vasculitic rash over both lower limbs, which did not respond to analgesia and …

View Full Text